Hyderabad, Feb. 25 -- The Indian Contract Research, Development, and Manufacturing Organization (CRDMO) sector is at an inflection point, with the potential to grow to $22 - $25 billion by 2035, according to a new report, Unleashing the Tiger: Indian CRDMO Sector 2025, published by Boston Consulting Group (BCG) and Innovative Pharmaceutical Services Organization (IPSO).
The report which was released during the inauguration of the two-day BioAsia 2025 Conclave here on Tuesday, highlighted India's strong foundation in small molecule capabilities, sustainable cost advantages and emerging biologics expertise, positioning the country as a global leader in pharmaceutical innovation.
IPSO is a newly formed industry body comprising eleven leading...